As one of the industry’s hottest research areas, which are drugs that harness the body’s immune system to fight cancer, a recent study on Bristol-Myers’s drug, Opdivo, proved immunotherapies might not be all they are hyped up to be.  A clinical trial revealed a surprise failure stating that Opdivo wasn’t significantly better than chemotherapy on patients with newly diagnosed lung cancer. Not only did this discovery knock Bristol-Myers from leading the market for cancer immunotherapies, but also it could be detrimental to the pharmaceutical industry.

Read Drug’s Failure Sows Therapy Doubt for more information about the results of Bristol-Myers’s clinical trial.